Chandigarh Herald

Parkinson’s Disease Clinical Trials and Therapies 2023: Latest breakthroughs, Treatment Market, Therapies, and Companies by DelveInsight | Abbvie, Roche, Kissei Pharmaceutical, Lundbeck, AstraZeneca

 Breaking News
  • No posts were found

Parkinson’s Disease Clinical Trials and Therapies 2023: Latest breakthroughs, Treatment Market, Therapies, and Companies by DelveInsight | Abbvie, Roche, Kissei Pharmaceutical, Lundbeck, AstraZeneca

April 18
23:00 2023
Parkinson’s Disease Clinical Trials and Therapies 2023: Latest breakthroughs, Treatment Market, Therapies, and Companies by DelveInsight | Abbvie, Roche, Kissei Pharmaceutical, Lundbeck, AstraZeneca
Parkinson’s Disease Pipeline

(New York, USA) DelveInsight’s, “Parkinson’s Disease Pipeline Insight, 2023” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the pipeline drug profiles, including Parkinson’s Disease clinical trial and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

To know more about the Parkinson’s disease drugs in pipeline, click here @ Parkinson’s Disease Drugs in different phases

 

Key takeaways from the Parkinson’s Disease Pipeline Insight Report

  • DelveInsight’s Parkinson’s disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson’s disease treatment.
  • The leading Parkinson’s Disease Companies working in the Parkinson’s Disease market are Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences,  Orpheris, Inc., Alkahest, Inc, and others.
  • Emerging Parkinson’s Disease Drugs Pipeline in various stages of development include Rotigotine, extended-release microspheres, LY03003, LY3884961, Methylprednisolone, Sirolimus, VY-AADC02, ERE-120: AAV2-NTN, Liatermin, MEDI1341, and others.
  • The Parkinson’s Disease Companies and academics that are working to assess challenges and seek opportunities that could influence Parkinson’s disease R&D. The Parkinson’s Disease pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Explore more information on the latest breakthroughs in the Parkinson’s Disease treatment landscape of the report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

 

Parkinson’s Disease Overview

Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson’s develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in movement.

 

Recent Developmental Activities in the Parkinson’s Disease Treatment Landscape

  • In December 2021, Pharma Two B Ltd., announced that its Phase III double-blind, active-controlled study of P2B001 in early Parkinson’s disease successfully met its primary and key secondary endpoints in the Phase III study, P2B001 was superior to each of its individual components as measured by the change from baseline to week 12 in total Unified Parkinson’s Disease Rating Scale (UPDRS Part II and III; primary endpoint). P2B001 was superior to the pramipexole component by 2.66 points (p=0.0018) and superior to the rasagiline component by 3.30 points (p=0.0001).
  • In December 2021, UCB announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule, alpha-synuclein misfolding inhibitor currently in Phase 2 clinical development, and upon completion of the ongoing Phase 1 program, an opt-in to co-develop UCB7853, an anti-alpha-synuclein antibody, both in Parkinson’s Disease (PD). 
  • In November 2021, Sio Gene Therapies Inc. provided a manufacturing and regulatory update for AXO-Lenti-PD, its clinical-stage gene therapy for Parkinson’s disease. Three GMP batches successfully completed fill and finish, achieving target titers using the updated suspension-based process
  • In October 2021, Inhibikase Therapeutics announced the dosing of the first Parkinson’s patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, an inhibitor for the treatment of Parkinson’s disease. 
  • In October 2021, AbbVie announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) was statistically superior to oral levodopa/carbidopa in reducing motor fluctuations in patients with advanced Parkinson’s disease (PD) in a Phase 3, randomized, double-blind, double-dummy, active-controlled study. The study met its primary endpoint of increase from baseline in “On” time (hours) without troublesome dyskinesia (involuntary movements) after 12 weeks based on the Parkinson’s Disease Diary (PD Diary). These results will be a key component of global regulatory submissions.

 

Find the information related to the Parkinson’s disease emerging therapies and companies @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

 

Parkinson’s Disease Emerging Drugs Profile 

Tavapadon: Cerevel Therapeutics

Tavapadon was designed to improve motor symptoms in Parkinson’s disease by selectively targeting and binding to dopamine D1/D5 receptor subtypes. Tavapadon differentially activates the direct motor pathway, potentially driving motor benefit while minimizing side effects typical of drugs that non-selectively stimulate dopamine, such as daytime sedation, or somnolence, compromised impulse control and risk of psychotic symptoms including hallucinations. Tavapadon is also designed to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor overexcitation and desensitization caused by full agonists, which can lead to dyskinesias and exacerbation of “off” time. Currently, it is in Phase III stage of clinical trial evaluation to treat Parkinson disease.

PT320: Peptron

PT320 is a sustained-release Exenatide (GLP1 agonist) for biweekly injection (Q2W). Due to its short half-life of 2.4 hours in the plasma of Exenatide, Peptron has developed a long-acting SR-Exenatide (PT320), resulting in sustained elevations of Exenatide for 20 days. With the result of preclinical and Phase I study of PT320, Peptron is testing the efficacy of PT320 of Parkinson’s disease in the on-going Phase II trial.

IkT-148009: Inhibikase Therapeutics

Inhibikase Therapeutics’ lead product candidate, IkT-148009, is a potent, selective small-molecule medication designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms.  

NLY01: Neuraly

NLY01 is a proprietary long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist. NLY01 penetrates the blood-brain barrier (BBB) in animal models and its receptor (GLP-1R) is highly expressed on glial cells. NLY01 is being developed as a disease-modifying agent for neurodegenerative disorders including Parkinson’s and Alzheimer’s disease. In clinically relevant animal models, NLY01 was found to prevent neuronal cell death by inhibition of microglial activation and formation of A1 neurotoxic astroglial cells. Treatment with NLY01 slowed disease progression, improved motor and cognitive functions and extended the lifespan in mice with Parkinson’s disease. 

 

Parkinsons Disease Therapeutics Assessment

There are approx. 140+ key Parkinson’s Disease companies which are developing the therapies. The companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.

 

For further information, refer to the detailed Parkinson’s Disease pipeline report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

 

Scope of the Parkinson’s Disease Pipeline Report

  • Coverage- Global
  • Parkinson’s Disease Companies- Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics, Cerevance, Aspen Neuroscience, Prilenia Therapeutics, Cortexyme Inc., Gain Therapeutics, Clexio Biosciences,  Orpheris, Inc., Alkahest, Inc., and many others.
  • Parkinson’s Disease Drugs- Rotigotine, extended-release microspheres, LY03003, LY3884961, Methylprednisolone, Sirolimus, VY-AADC02, ERE-120: AAV2-NTN, Liatermin, MEDI1341, and others.

 

Request for sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

 

Table of Content

  1. Introduction
  2. Parkinson’s Disease Executive Summary
  3. Parkinson’s Disease: Overview
  4. Parkinson’s Disease Pipeline Therapeutics
  5. Parkinson’s Disease Therapeutic Assessment
  6. Parkinson’s Disease – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tavapadon: Cerevel Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Prasinezumab : Roche
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. MEDI1341: AstraZeneca
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Neural microtissues: Treefrog Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Parkinson’s Disease Companies
  21. Parkinson’s Disease Key Products
  22. Parkinson’s Disease- Unmet Needs
  23. Parkinson’s Disease- Market Drivers and Barriers
  24. Parkinson’s Disease- Future Perspectives and Conclusion
  25. Parkinson’s Disease Analyst Views
  26. Parkinson’s Disease Key Companies
  27. Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting